Your browser doesn't support javascript.
loading
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China.
Zhao, Minmin; Qiu, Shanhu; Wu, Xin; Miao, Pengcheng; Jiang, Zhi; Zhu, Tao; Xu, Xizhong; Zhu, Yanling; Zhang, Bei; Yuan, Donglan; Zhang, Yang; Sun, Wei; He, Aiqin; Zhao, Min; Hou, Wenjie; Zhang, Yingli; Shao, Zhuyan; Jia, Meiqun; Li, Mei; Chen, Jun; Xu, Jingcheng; Chen, Bingwei; Zhou, Ying; Shen, Yang.
Affiliation
  • Zhao M; Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, No. 87 Dingjiaqiao, Nanjing, 210009, China.
  • Qiu S; Department of General Practice, Zhongda Hospital, Institute of Diabetes, School of Medicine, Southeast University, Nanjing, 210009, China.
  • Wu X; Department of Gynecological Oncology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200090, China.
  • Miao P; Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, No. 87 Dingjiaqiao, Nanjing, 210009, China.
  • Jiang Z; Department of Gynecologic Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, China.
  • Zhu T; Department of Gynecological Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, 310005, China.
  • Xu X; Department of Gynecology, Affiliated Hospital of Jiangnan University, Wuxi, 214122, China.
  • Zhu Y; Department of Gynecology Oncology, Xuzhou Cancer Hospital, Xuzhou, 221005, China.
  • Zhang B; Department of Obstetrics and Gynecology, Xuzhou Central Hospital, Xuzhou, 221009, China.
  • Yuan D; Department of Gynecological Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, 225317, China.
  • Zhang Y; Department of Gynecology, Lianyungang First People's Hospital, Lianyungang, 222002, China.
  • Sun W; Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
  • He A; Department of Gynecology Oncology, Nantong Tumor Hospital, Nantong, 226361, China.
  • Zhao M; Department of Gynecological Oncology, Wuxi Maternal and Child Health Hospital, Wuxi School of Medicine, Jiangnan University, Wuxi, 214002, China.
  • Hou W; Department of Obstetrics and Gynecology, Dushu Lake Hospital Affiliated to Soochow University (Soochow University Medical Center), Suzhou, 215125, China.
  • Zhang Y; Department of Gynecological Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, 310005, China.
  • Shao Z; Department of Gynecological Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, 310005, China.
  • Jia M; Department of Gynecology Oncology, Nantong Tumor Hospital, Nantong, 226361, China.
  • Li M; Department of Oncology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, China.
  • Chen J; Medical Affair Department, Zai Lab (Shanghai) Co., Ltd, Shanghai, 201210, China.
  • Xu J; Medical Affair Department, Zai Lab (Shanghai) Co., Ltd, Shanghai, 201210, China.
  • Chen B; Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, No. 87 Dingjiaqiao, Nanjing, 210009, China. drchenbw@126.com.
  • Zhou Y; Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, No. 17 Lujiang Road, Hefei, 230001, China. caddiezy@ustc.edu.cn.
  • Shen Y; Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, No. 87 Dingjiaqiao, Nanjing, 210009, China. shenyang@seu.edu.cn.
Target Oncol ; 18(6): 869-883, 2023 Nov.
Article in En | MEDLINE | ID: mdl-37847485
Maintenance therapy with poly (ADP-ribose) polymerase inhibitors is a new option for patients with ovarian cancer (OC) after they have received platinum-based chemotherapy to reduce the recurrence or relapse rates, but it remains unclear whether there are any changes in efficacy and safety when different starting doses of niraparib are administrated to Chinese patients, who typically have a bodyweight < 77 kg. We found that niraparib exhibited satisfactory efficacy with tolerable safety during maintenance therapy for advanced OC whether administered at 100 mg or 200 mg doses. We believe these regimens can serve as a valuable addition to the previous results of randomized controlled trials.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms Limits: Aged / Female / Humans Language: En Journal: Target Oncol Journal subject: NEOPLASIAS Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms Limits: Aged / Female / Humans Language: En Journal: Target Oncol Journal subject: NEOPLASIAS Year: 2023 Document type: Article Affiliation country: Country of publication: